Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis

Journal of the Neurological Sciences

Volumn 290, Issue 1-2, 2010, Pages 16-21

  Liggett, Thomas ^a   Melnikov, Anatoliy ^a   Tilwalli, Shilpa ^a   Yi, Qilong ^b   Chen, Haiyan ^b   Replogle, Charles ^b   Feng, Xuan ^c   Reder, Anthony ^c   Stefoski, Dusan ^a   Balabanov, Roumen ^a   Levenson, Victor ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b ScienceDocs Inc   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Biomarker; Cell free plasma DNA; DNA methylation; Gene promoter; Microarray; Multiple sclerosis

Indexed keywords

CELL FREE PLASMA DNA; DNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA METHYLATION; FEMALE; HUMAN; MALE; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REMISSION;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; DNA; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; FEMALE; GENETIC MARKERS; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMA; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; SENSITIVITY AND SPECIFICITY; UP-REGULATION;

EID: 74849112968     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.12.018     Document Type: Article

References (43)

1. Compston A., and Coles A. Multiple sclerosis. Lancet 372 9648 (2008) 1502-1517
2. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58 6 (2005) 840-846
3. Bielekova B., and Martin R. Development of biomarkers in multiple sclerosis. Brain 127 Pt 7 (2004) 1463-1478
4. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 349 2 (2003) 139-145
5. Dore-Duffy P., Newman W., Balabanov R., Lisak R.P., Mainolfi E., Rothlein R., et al. Circulating, soluble adhesion proteins in cerebrospinal fluid and serum of patients with multiple sclerosis: correlation with clinical activity. Ann Neurol 37 1 (1995) 55-62
6. Freedman M.S., Thompson E.J., Deisenhammer F., Giovannoni G., Grimsley G., Keir G., et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 62 6 (2005) 865-870
7. Rejdak K., Petzold A., Stelmasiak Z., and Giovannoni G. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 14 1 (2008) 59-66
8. Whitaker J.N. Myelin basic protein in cerebrospinal fluid and other body fluids. Mult Scler 4 1 (1998) 16-21
9. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., et al. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet 15 18 (2006) 2813-2824
10. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 39 9 (2007) 1083-1091
11. Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 357 9 (2007) 851-862
12. Oksenberg J.R., Baranzini S.E., Sawcer S., and Hauser S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 9 7 (2008) 516-526
13. Baylin S.B. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 Suppl 1 (2005) S4-S11
14. Delgado J. Novel epigenetic targets in lymphoproliferative disorders. Curr Cancer Drug Targets 8 5 (2008) 378-391
15. Sanchez-Pernaute O., Ospelt C., Neidhart M., and Gay S. Epigenetic clues to rheumatoid arthritis. J Autoimmun 30 1-2 (2008) 12-20
16. Strickland F.M., and Richardson B.C. Epigenetics in human autoimmunity. Epigenetics in autoimmunity - DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity 41 4 (2008) 278-286
17. Casaccia-Bonnefil P., Pandozy G., and Mastronardi F. Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis. Prog Neurobiol 86 4 (2008) 368-378
18. Chao M.J., Ramagopalan S.V., Herrera B.M., Lincoln M.R., Dyment D.A., Sadovnick A.D., et al. Epigenetics in multiple sclerosis susceptibility: difference in transgenerational risk localizes to the major histocompatibility complex. Hum Mol Genet 18 2 (2009) 261-266
19. Bearzatto A., Conte D., Frattini M., Zaffaroni N., Andriani F., Balestra D., et al. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res 8 12 (2002) 3782-3787
20. Anker P., Stroun M., and Maurice P.A. Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. Cancer Res 35 9 (1975) 2375-2382
21. Leon S.A., Shapiro B., Sklaroff D.M., and Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37 3 (1977) 646-650
22. Lo Y.M., Rainer T.H., Chan L.Y., Hjelm N.M., and Cocks R.A. Plasma DNA as a prognostic marker in trauma patients. Clin Chem 46 3 (2000) 319-323
23. Rainer T.H., Wong L.K., Lam W., Yuen E., Lam N.Y., Metreweli C., et al. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem 49 4 (2003) 562-569
24. Melnikov A., Scholtens D., Godwin A., and Levenson V. Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn 11 1 (2009) 60-65
25. Melnikov A.A., Scholtens D., Talamonti M.S., Bentrem D.J., and Levenson V.V. Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol 99 2 (2009) 119-122
26. Giacona M.B., Ruben G.C., Iczkowski K.A., Roos T.B., Porter D.M., and Sorenson G.D. Cell-free DNA in human blood plasma: length measurements in patients with pancreatic cancer and healthy controls. Pancreas 17 1 (1998) 89-97
27. Christensen B.C., Houseman E.A., Marsit C.J., Zheng S., Wrensch M.R., Wiemels J.L., et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 5 8 (2009) e1000602
28. Gelman A.E., Zhang J., Choi Y., and Turka L.A. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol 172 10 (2004) 6065-6073
29. Kabelitz D. Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol 19 1 (2007) 39-45
30. Vollmer J., Tluk S., Schmitz C., Hamm S., Jurk M., Forsbach A., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 202 11 (2005) 1575-1585
31. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., and Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416 6881 (2002) 603-607
32. Pietschmann K., Beetz S., Welte S., Martens I., Gruen J., Oberg H.H., et al. Toll-like receptor expression and function in subsets of human gammadelta T lymphocytes. Scand J Immunol 70 3 (2009) 245-255
33. Brentano F., Schorr O., Gay R.E., Gay S., and Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 52 9 (2005) 2656-2665
34. Holm C.K., Petersen C.C., Hvid M., Petersen L., Paludan S.R., Deleuran B., et al. TLR3 ligand polyinosinic:polycytidylic acid induces IL-17A and IL-21 synthesis in human Th cells. J Immunol 183 7 (2009) 4422-4431
35. Komatsuda A., Wakui H., Iwamoto K., Ozawa M., Togashi M., Masai R., et al. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 152 3 (2008) 482-487
36. Nakano S., Morimoto S., Suzuki J., Nozawa K., Amano H., Tokano Y., et al. Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 47 2 (2008) 145-149
37. Prinz M., Garbe F., Schmidt H., Mildner A., Gutcher I., Wolter K., et al. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest 116 2 (2006) 456-464
38. Duramad O., Fearon K.L., Chang B., Chan J.H., Gregorio J., Coffman R.L., et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 174 9 (2005) 5193-5200
39. Fischer M., and Ehlers M. Toll-like receptors in autoimmunity. Ann N Y Acad Sci 1143 (2008) 21-34
40. Hansen B.S., Hussain R.Z., Lovett-Racke A.E., Thomas J.A., and Racke M.K. Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J Neuroimmunol 172 1-2 (2006) 94-103
41. Krieg A.M., and Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 220 (2007) 251-269
42. Melnikov A.A., Scholtens D.M., Wiley E.L., Khan S.A., and Levenson V.V. Array-based multiplex analysis of DNA methylation in breast cancer tissues. J Mol Diagn 10 1 (2008) 93-101
43. Liggett T, Melnikov A, Yi Q, Replogle C, Brand R, Kaul K, Talamonti M, Abrams R, Levenson V. Differential methylation of cell-free circulating DNA in patients with pancreatic cancer and chronic pancreatitis. Cancer. in press.